Open AccessRomiplostim for management of refractory immune thrombocytopenic purpura in the immediate postpartum period
Author(s) -
A Patras,
Reinaldo Figueroa,
Amit Singh,
Ichchha Madan
Publication year - 2020
Publication title -
bmj case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.231
H-Index - 26
ISSN - 1757-790X
DOI - 10.1136/bcr-2020-234335
Subject(s) - romiplostim , medicine , thrombocytopenic purpura , thrombopoietin , postpartum period , pediatrics , eltrombopag , thrombopoietin receptor , refractory (planetary science) , intensive care medicine , pregnancy , immunology , immune system , immune thrombocytopenia , antibody , genetics , stem cell , haematopoiesis , biology , physics , astrobiology
We present a case of a pregnant woman with chronic immune thrombocytopenic purpura and chronic hypertension who developed pre-eclampsia with severe features warranting delivery. Her overall clinical picture and liver enzymes improved in the immediate postpartum period, however, aggressively progressing thrombocytopenia posed a diagnostic dilemma to the interdisciplinary care team. After failing to respond to first-line therapies including high-dose corticosteroids and intravenous immunoglobulin, she was successfully managed with a trial of the thrombopoietin receptor agonist, Romiplostim.